Teva Sues Kyowa Hakko Over Pravachol Patent Infringement
This article was originally published in PharmAsia News
Executive Summary
Israel's Teva Pharmaceutical Industries, the world's largest maker of generic drugs, filed a suit against Kyowa Hakko Kogyo on grounds the Japanese firm violated a patent held by Teva's Hungarian subsidiary. The suit involves a compound for an anti-cholesterol Pravachol (pravastatin sodium), patented in the United States by Bristol Myers Squibb, and for which the Teva subsidiary received a Japanese patent in 2005. Kyowa Hakko said it began producing the raw material in 2003 as the basis for a generic drug it now sells on the domestic Japanese market. The year before, a forerunner of Daiichi Sankyo had owned the Pravachol compound until its patent expired in 2002. (Click here for more - may require a subscription
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.